Skip to main content
. Author manuscript; available in PMC: 2020 Jan 10.
Published in final edited form as: Cell Rep. 2019 Dec 24;29(13):4460–4470.e8. doi: 10.1016/j.celrep.2019.11.084

Figure 6. Rare Individuals Have High Levels of RBS-Targeting Antibodies in Serum.

Figure 6.

ELISAs were completed with serum from Donor 019-10117 with plates coated with mammalian-expressed recombinant A/Victoria/210/2009-WT HA (Vic/09 WT), A/Hong Kong/4801/2014-WT HA (HK/14 WT), and Y98F HA RBS mutants of both strains (Vic/09 Y98F, HK/14 Y98F).

(A and B) ELISAs were completed with serum collected before vaccination (day 0) (A) or 21 days after vaccination (B). Serum antibodies collected pre- and post-vaccination from 019-10117 exhibited reduced binding to A/Victoria/210/2009 HA with the Y98F substitution and the A/Hong Kong/4801/2014 HA with the Y98F substitution. Dashed lines represent the 95% CI for each site, specific binding curve fit. Data shown are from three independent experiments.